Idelalisib

Back to search

Molecule Structure

Scientific Name

Idelalisib

Description of the Drug

Idelalisib is an antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09054

Brand Name(s)

Zydelig

Company Owner(s)

Gilead Sciences Inc

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
PI3-kinase p110-delta subunit SINGLE PROTEIN INHIBITOR CHEMBL3130

Unichem Links

SureChEMBL SCHEMBL356400 SCHEMBL16782604
DrugBank DB09054
PubChem: Thomson Pharma 16728852
PubChem 11625818
LINCS LSM-1205
Nikkaji J3.231.674C
PDBe 40L
BindingDB 150175 50403068
DrugCentral 4878
Brenda 213179 213206 19712
ChemicalBook CB32538915 CB62638450
Guide to Pharmacology 6741
rxnorm IDELALISIB ZYDELIG
PubChem: Drugs of the Future 136350004
ChEBI 82701
ZINC ZINC000013986658